NCT06409832 RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment
| NCT ID | NCT06409832 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Florence |
| Condition | Migraine |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-03-26 |
| Primary Completion | 2027-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2024-03-26 with a primary completion date of 2027-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of rimegepant as preventive migraine treatment in a cohort of episodic or chronic migraine patients.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the 3rd edition of the International Classification of Headache Disorder (ICHD-III); * At least 4 monthly migraine days; * Good compliance to study procedures; * Availability of headache diary at least of the preceding months before enrollment. Exclusion Criteria: * Subjects with contraindications for use of gepants; * Concomitant diagnosis of medical diseases and/or comorbidities that, in the Investigator's opinion might interfere with study assessments; * medical comorbidities that could interfere with study results; * Pregnancy and breastfeeding. * Changes in preventive treatments in the month before the first administration of rimegepant
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06409832 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Migraine. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06409832 currently recruiting?
Yes, NCT06409832 is actively recruiting participants. Contact the research team at luigifrancesco.iannone@unimore.it for enrollment information.
Where is the NCT06409832 trial being conducted?
This trial is being conducted at Florence, Italy, Pavia, Italy.
Who is sponsoring the NCT06409832 clinical trial?
NCT06409832 is sponsored by University of Florence. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.